When was Biocartis founded?

Biocartis was founded in 2007 and raised its 1st funding round 2 years after it was founded.

Where is Biocartis located?

Biocartis is headquartered in Mechelen, Belgium. It is registered at Jersey City, New Jersey.

How many employees does Biocartis have?

As of Jul 31, 2026, the latest employee count at Biocartis is 350.

Is Biocartis a funded company?

Biocartis is a funded company, having raised a total of $305M across 18 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 15, 2009.

When was the latest funding round of Biocartis?

Biocartis' latest funding was a $***** Post IPO round on Sep 01, 2022, with participation from 0 investor.

What is the annual revenue of Biocartis?

Annual revenue of Biocartis is between €10M and €50M as on Dec 31, 2024

Where does Biocartis rank among its competitors?

Biocartis ranks 6th amongst 252 active competitors, of which 68 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was GRAIL, which secured $110M in Jun, 2026.

Who are the top competitors of Biocartis?

Biocartis' top competitors include GRAIL, Exact Sciences and UDX. Among them, GRAIL secured the most recent funding round in June, 2026.

Biocartis - 2026 Company Profile, Team, Funding, Competitors & Financials

Biocartis is a public company based in Mechelen (Belgium), founded in 2007 by Rudi Pauwels. It operates as a Manufacturer of automated molecular diagnostic systems for oncology biomarker testing. Biocartis has raised $305M in funding from investors like Johnson & Johnson Innovation – JJDC, Aescap and Debiopharm. The company has 252 active competitors, including 68 funded and 44 that have exited. Its top competitors include companies like GRAIL, Exact Sciences and UDX.

Company Details

Manufacturer of automated molecular diagnostic systems for oncology biomarker testing. These systems perform molecular analysis on tissue samples to detect genetic mutations and gene fusions. The technology supports clinical decision-making by providing results for various cancer types. The hardware and associated assays facilitate the identification of biomarkers required for treatment selection.

Website: www.biocartis.com/en-US
Social
Email ID: *****@biocartis.com
Phone Number: +32 **********
Registered Address: Jersey City, New Jersey

Key Metrics

Founded Year

2007

Location

Mechelen, Belgium

Stage

Public

Total Funding

$305M in 18 rounds

Latest Funding Round

Post IPO, Sep 01, 2022, $*****

Investors

Johnson & Johnson Innovation – JJDC & 19 more

Ranked

6^th among 252 active competitors

Annual Revenue

€10M - €50M as on Dec 31, 2024

Employee Count

350 as on Jul 31, 2026

Investment & Acquisitions

Pronota

Similar Companies

GRAIL & 272 more

Exit Details

Public

View Biocartis' full profile

Biocartis is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Biocartis Nv CIN: 0827.475.227 , Belgium, Active	Jun 30, 2010	€10M - €50M (As on Dec 31, 2024)	407 (As on Dec 31, 2021)	-
BIOCARTIS US, INC. CIN: 300975380 , United States, Active	Dec 26, 999	-	26 (As on Dec 31, 2024)	-

Biocartis got listed on Apr 27, 2015.

Click here to take a look at Biocartis's IPO in detail

Biocartis has raised a total funding of $305M over 18 rounds. Its first funding round was on Oct 15, 2009. Biocartis has 20 institutional investors.

Here is the list of recent funding rounds of Biocartis:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 01, 2022	1469725	Post IPO	5995237	5935577	1423958	2696949
May 11, 2021	3770825	Grant (prize money)	4957755	9693083	3751642	VLAIO
Dec 07, 2020	9200767	Post IPO	8902526	5047400	4497476	1847713

Access funding benchmarks and valuations. Sign up today!

View details of Biocartis's funding rounds and investors

The founders of Biocartis is Rudi Pauwels.

Here are the details of Biocartis' key team members:

Rudi Pauwels: Former Founder of Biocartis.

View details of Biocartis's Founder profiles and Board Members

Biocartis' employee count trend

Biocartis has 350 employees as of Jul 26. Here is Biocartis's employee count trend over the years:

Uncover Biocartis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Biocartis include GRAIL, Exact Sciences and UDX. Here is the list of Top 10 competitors of Biocartis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	GRAIL 2016, Menlo Park (United States), Public	Developer of a screening platform for circulating tumor DNA to detect cancer	$2B	Arch Venture Partners, Google Ventures & 52 others	71/100
2nd	Exact Sciences 1995, Madison (United States), Acquired	Provider of non-invasive molecular diagnostic testing solutions for cancer	-	Petrillo Capital, Back Bay Group & 8 others	71/100
3rd	UDX 2012, Seville (Spain), Series C	Developer of non-invasive blood-based diagnostics for cancer	$105M	Quest Diagnostics, Olympus & 6 others	67/100
4th	Stilla Technologies 2013, Villejuif (France), Acquired	Developer of digital PCR solution for research	$53.1M	Illumina Ventures, LBO France & 11 others	64/100
5th	Volition 1995, Gembloux (Belgium), Public	Developer of cancer diagnostic tests	-	Namur Invest, Belgium & 1 others	61/100
6th	Biocartis 2007, Mechelen (Belgium), Public	Manufacturer of automated molecular diagnostic systems for oncology biomarker testing	$305M	Advent Life Sciences, Philips & 18 others	58/100
7th	NeuMoDx 2012, Ann Arbor (United States), Acquired	Developer of a platform for low cost molecular testing	$66M	Arboretum Ventures, Wolverine Venture Fund ... & 3 others	58/100
8th	Biovica 2009, Uppsala (Sweden), Public	Drug response monitoring assay	$4.27M	EIC Fund, Europa	55/100
9th	Tethis 2004, Milan (Italy), Series A	Provider of automated solutions for in liquid biopsy	$15.3M	sanpaolope.com, Indaco Venture Partners & 5 others	55/100
10th	Mursla 2017, London (United Kingdom), Seed	Provider of diagnostic device for cancer detection	$547K	Future Fund, TA Ventures & 26 others	55/100